Inovio Pharmaceuticals (INO) Non Operating Interest Expenses (2019 - 2024)

Inovio Pharmaceuticals has disclosed Non Operating Interest Expenses across 6 years of filings, most recently posting $177833.0 for Q1 2024.

• In Q1 2024, Non Operating Interest Expenses fell 43.27% year-over-year to $177833.0; the TTM figure through Dec 2024 stood at $177833.0 (down 85.46% YoY), while the FY2024 annual figure was $177833.0, down 85.46% from the prior year.
• Non Operating Interest Expenses came in at $177833.0 for Q1 2024 at Inovio Pharmaceuticals, down from $282325.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $2.8 million in Q2 2020 to a low of $177833.0 in Q1 2024.
• Average Non Operating Interest Expenses over 5 years is $781968.9, with a median of $313488.0 recorded in 2022.
• Year-over-year, Non Operating Interest Expenses soared 327.24% in 2020 and plunged 83.6% in 2021.
• Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2020, then plunged by 55.03% to $480313.0 in 2021, then slumped by 34.73% to $313488.0 in 2022, then retreated by 9.94% to $282325.0 in 2023, then slumped by 37.01% to $177833.0 in 2024.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $177833.0 in Q1 2024, $282325.0 in Q4 2023, and $313488.0 in Q3 2023.